Using redifferentiation medicines before radioactive iodine for thyroid cancer
Part of Cancer, Hormones & metabolism clinical trials.
This study collects information on how redifferentiation medicines used before radioactive iodine work in everyday care for certain thyroid cancers that are unlikely to respond to radioactive iodine. It may help doctors understand the best real-world way to use these medicines to plan and deliver treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be age 18 or older when you sign consent.
- You have thyroid cancer that is unlikely to respond to radioactive iodine, or it no longer responds to it.
- Your care plan will include giving a redifferentiation medicine before you get radioactive iodine for diagnosis and/or treatment.
- You have not used redifferentiation medicines outside a clinical trial, or—if you have—your team will collect past details and you’ll also share new details after consent.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies how well radioactive iodine treatment works for people with certain types of thyroid cancer that have a low or intermediate risk of coming back. It aims to see if this treatment is effective and safe for these patients.
This study compares two approaches after thyroid surgery: giving radioactive iodine right away versus deciding based on follow-up test results. It aims to see which approach better helps people with intermediate-risk differentiated thyroid cancer.
This trial tests how much radiation a specialized whole-body PET/CT scan delivers in patients with differentiated thyroid cancer. It may help doctors better plan treatment for cancer that persists, returns, or has spread—especially when radioactive iodine (RAI) may or may not work.
This trial offers a decision aid to help you choose whether to have radioactive iodine (RAI) treatment after thyroid cancer surgery. You may qualify if you have intermediate-risk thyroid cancer and haven't yet made a decision about RAI.
This trial is testing whether giving radiation therapy after thyroid surgery can help destroy any leftover cancer cells in people with high-risk differentiated thyroid cancer. It is for those who had surgery but some cancer was still left behind.
This study compares two ways of replacing thyroid hormone after radioactive iodine therapy for high-risk thyroid cancer. It aims to find which approach is more effective and better for patients.
Hear when a new Thyroid Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.